Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective

References

• Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation109, 1101–1107 (2004).
   PubMed Web of Science ®Google Scholar
• The SEARCH Collaborative Group SLCO1B1 Variants and Statin-Induced Myopathy – a Genomewide Study. N. Engl. J. Med.359, 1–11 (2008).
   PubMed Web of Science ®Google Scholar
• Chan PSN. Incremental benefit and cost–effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation115(18), 2398–2409 (2007).
   PubMed Web of Science ®Google Scholar
• Ara R, Pandor A, Stevens J, Rees A, Rafia R. Early high dose lipid-lowering therapy to avoid cardiac events – a systematic review and economic evaluation. Health Technol. Assess.13(34), 1–74, 75–118 (2009) (In press).
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA292(11), 1307–1316 (2004).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med.350(15), 1495–1504 (2004).
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA294(19), 2437–2445 (2005).
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med.352(14), 1425–1435 (2005).
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366, 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Packham C, Gray D, Silcocks P, Hampton J. Identifying the risk of death following hospital discharge in patients admitted with a suspected acute myocardial infarction in whom the diagnosis is not confirmed. Eur. Heart J.21, 213–219 (2000).
   PubMed Web of Science ®Google Scholar
• Kaplan RC, Heckbert SR, Furberg CD, Psaty BM. Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. J. Clin. Epidemiol.55(7), 654–664 (2002).
   PubMed Web of Science ®Google Scholar
• Ward S, Lloyd Jones M, Pandor A et al. Systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol. Assess.11(14), 1–160, iii–iv (2007).
   Google Scholar
• Gray D, Hapton JR. Twenty years’ experience of myocardial infarction: the value of a heart attack register. Nottingham Heart Attack Register. Br. J. Clin. Pharmacol.47, 292–295 (1993).
   Web of Science ®Google Scholar
• Fox K, Poole-Wilson P, Clayton T, Henderson R, Shaw T, Wheatley D. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet366(9489), 914–920 (2005).
   PubMed Web of Science ®Google Scholar
• Henderson R, Pocock SJ, Clayton A. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J. Am. Coll. Cardiol.42(7), 1161–1170 (2008).
   Google Scholar
• Wolfe CDA, Rudd AG, Howard R, Coshall C. Incidence and case fatality rates of stroke subtypes in a multiethnic population: the South London Stroke Register. J. Neurol. Neurosurg. Psychiatr.72, 211–216 (2002).
   PubMed Web of Science ®Google Scholar
• Tsevat J, Kuntz KM, Orav EJ, Weinstein MC, Sacks FM, Goldman L. Cost–effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am. Heart J.141, 727–734 (2001).
   PubMed Web of Science ®Google Scholar
• Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ316(7133), 736–741 (1998).
   PubMed Web of Science ®Google Scholar
• Ara R, Brazier J. The issues involved in populating an economic model with utility values: moving towards better practice. Presented at: Health Technology Assessment International (HTAi). Singapore, 21–24 June 2009.
   Google Scholar
• Silva M, Matthews ML, Jarvis C et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin. Ther.29, 253–260 (2007).
   PubMed Web of Science ®Google Scholar
• Insull W. The problem of compliance to cholesterol altering therapy. J. Intern. Med.241, 317–325 (1997).
   PubMed Web of Science ®Google Scholar
• Jackevicius CAM, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA288, 462–467 (2002).
   PubMed Web of Science ®Google Scholar
• Benner JS. Long-term persistence in use of statin therapy in elderly patients. JAMA288, 455–461 (2002).
   PubMed Web of Science ®Google Scholar
• Wei L, Wang J, Thompson P et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart88, 229–233 (2002).
   PubMed Web of Science ®Google Scholar
• Blackburn DF, Dobson RT, Blackburn JL et al. Adherence to statins, β-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can. J. Cardiol.21, 485–488 (2005).
   PubMed Web of Science ®Google Scholar
• Penning-van Beest FJ, Termorshuizen F, Goettsch WG et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur. Heart J.28(2), 154–159 (2007).
   PubMed Web of Science ®Google Scholar
• Howell N, Trotter R, Mottram DR, Rowe PH. Compliance with statins in primary care. Pharma. J.272, 23–26 (2004).
   Google Scholar
• Cramer JA. Effect of partial compliance on cardiovascular medication effectiveness. Heart88, 203–206 (2002).
   PubMed Web of Science ®Google Scholar
• Huser MA, Evans TS, Berger V. Medication adherence trends with statins. Adv. Ther.22, 163–171 (2005).
   PubMed Web of Science ®Google Scholar
• Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E, Wallentin L. Fast Revascularisation During Instability in Coronary Artery Disease (FRISC-II) investigators. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet368(9540), 998–1004 (2006).
   PubMed Web of Science ®Google Scholar
• Bach RG. The early invasive strategy revisited: FRISC II at 5 years. Lancet368(9540), 966–969 (2006).
   Google Scholar
• Mehta SR, Yusuf S, Peters RJ et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet358(9281), 527–533 (2001).
   PubMed Web of Science ®Google Scholar
• Lewis BS, Mehta SR, Fox KA et al. CURE trial investigators. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Am. Heart J.150(6), 1177–1184 (2005).
   PubMed Web of Science ®Google Scholar
• Jolly SS, Pogue J, Haladyn K et al. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur. Heart J.30(8), 900–907 (2008).
   Google Scholar
• Boden WE, O’Rourke RA, Teo KK et al. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med.356, 1503–1516 (2007).
   PubMed Web of Science ®Google Scholar
• Herlitz J, McGovern P, Dellborg M et al. Comparison of treatment and outcomes for patients with acute myocardial infarction in Minneapolis/St. Paul, Minnesota, and Göteborg, Sweden. Am. Heart J.146(6), 1023–1029 (2003).
   Google Scholar
• Grundy SM. The issue of statin safety: where do we stand? Circulation111, 3016–3019 (2005).
   PubMed Web of Science ®Google Scholar